<DOC>
	<DOCNO>NCT00874406</DOCNO>
	<brief_summary>The purpose study investigate whether preoperative TAC able improve progression free survival overall survival patient receive liver metastasis resection colorectal cancer .</brief_summary>
	<brief_title>Preoperative Transhepatic Arterial Chemotherapy ( TAC ) Treatment Liver Metastasis Resectable Colorectal Cancer</brief_title>
	<detailed_description>We administer TAC ( oxaliplatin , FUDR MMC ) 7 day liver metastasis resection colorectal cancer . The study endpoint progression free survival overall survival evaluate intent-to-treat analysis .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<criteria>age &lt; = 75 year resectable liver metastasis remnant liver volume &gt; = 70 % without organ metastasis peritoneum metastasis without contradiction cardiac pulmonary disease age &gt; 75 year unresectable liver metastasis remnant liver volume &lt; 50 % organ metastasis peritoneum metastasis contradiction cardiac pulmonary disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>colorectal cancer</keyword>
	<keyword>liver metastasis</keyword>
	<keyword>neoadjuvant chemotherapy</keyword>
</DOC>